<DOC>
	<DOCNO>NCT02212587</DOCNO>
	<brief_summary>The objective study determine tobramycin inhalation powder ( TIP ) reduce amount Burkholderia Cepacia Complex ( BCC ) species - type bacteria , sputum cystic fibrosis patient .</brief_summary>
	<brief_title>Tobramycin Inhalation Powder ( TIP ) Cystic Fibrosis Patients Infected With Burkholderia Cepacia Complex</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Tobramycin</mesh_term>
	<criteria>Age 6 year old Diagnosis CF base following : sweat chloride &gt; 60 mEq/L genotype 2 identifiable mutation consistent CF ; one clinical feature consistent CF . Chronically infect Burkholderia cepacia complex specie ( &gt; 50 % respiratory specimens positive 24 month prior screen ) . Able produce sputum ( expectorate induce ) . Able reproducibly perform pulmonary function test . Written inform consent provide . Post lung transplantation . Pregnancy . Acute exacerbation require IV oral antibiotic within 14 day Patients currently receive inhale tobramycin/TOBI A septic clinically unstable patient , determine investigator .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>inhale antibiotic</keyword>
</DOC>